Hu Yanan, Li Jiacheng, Jin Yana, Liu Ruipu, Yang Yifan, Chen Chuhan, Duan Jianfei, Wang Hong, Su Lihua
Objective To analyze the current situation of high rates leukemia DRG cases in a certain hematology hospital, and provide more optimized solutions for targeted cost control, reducing patients' medical burden, and promoting the rational use of medical insurance funds for high rates cases. Methods Leukemia cases discharged from a blood disease specialist hospital in Tianjin from April 1, 2024 to April 1, 2025 were extracted, and patient data paid according to the high-cost case payment standard were screened. Their basic information was analyzed, and the grey correlation analysis method was used to analyze the correlation between each sub item cost of high-cost cases and the total hospitalization cost. At the same time, typical cases were selected for key analysis. Results In the 2024 agreement year, the hospital settled a total of 7,256 cases according to DRG, of which 335 cases were paid according to high-cost cases, accounting for 4.62 % of the total cases. Grey correlation analysis found that the overall drug cost and total hospitalization cost of high-cost cases had the highest correlation. Among the top 12 high-cost DRG groups with the highest number of cases, 6 DRG groups had the strongest correlation between drug cost and hospitalization cost, 4 DRG groups had the strongest correlation between examination cost and hospitalization cost, and 2 DRG groups had the strongest correlation between treatment cost and hospitalization cost. Conclusion The correlation between drug costs, examination costs, treatment costs, and the total cost of high incidence cases is the highest, which is the key to controlling the cost of high incidence cases of leukemia DRG. Optimizing clinical diagnosis and treatment, improving medical insurance payment policies, and strengthening hospital management are effective strategies for addressing high rates of cases.